Epithelial ovarian cancer is the leading cause of death from gynecological cancers, largely owing to the development of recurrent intractable disease. Only a small number of distinct genetic mutations ...

Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding ...

PHST001 targets CD24, a protein that helps tumors evade immune destruction, potentially enhancing immune response against cancer cells. The FDA's fast track designation accelerates the development and ...

A new research paper was published in Volume 16 of Oncotarget on September 22, 2025, titled "Loss of Trp53 results in a hypoactive T cell phenotype accompanied by reduced pro-inflammatory signaling in ...

Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...

Bevacizumab addition to chemotherapy showed significant progression-free survival benefits in high-risk epithelial ovarian cancer patients but not in overall survival. The BEV1L study used real-world ...

A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled “Bridging clinical insight and ...

A malignant tumor that begins in the ovaries is called ovarian cancer. There are several types of ovarian cancer. Ovarian cancer that begins on the surface of the ovary (epithelial carcinoma) is the ...

The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with ...